Cryosite operates in clinical-trial logistics and biobanking, offering outsourced services across ambient, cold, frozen, ultra-frozen and cryogenic storage environments. This positions the company as a supporting player in the growing pharmaceutical, cell and gene-therapy ecosystem, where reliable temperature-controlled handling is critical.
Alterity has continued to advance ATH434 through late 2025 and into 2026. The company reported positive results from its ATH434-202 Phase 2 trial in MSA, and in March 2026 said it received positive feedback from the US Food and Drug Administration following a Type …
Artrya (ASX:AYA) attracted investor attention on Thursday, 10 September 2026, after facing selling pressure during a weaker Australian sharemarket session. The S&P/ASX 200 (ASX:XJO) closed at 8,819.40 points, down 1.03%, as investors reassessed risk exposure amid higher yields and changing market conditions.
Echo IQ (ASX:EIQ) faced significant investor attention on Thursday, 10 September 2026, following continued pressure after the company’s regulatory update regarding its EchoSolv HF product. The S&P/ASX 200 (ASX:XJO) closed at 8,819.40 points, down 1.03%, as broader market sentiment remained cautious.
Tetratherix is built around Tetramatrix, a patented injectable "biostealth" material that flows during application and then solidifies inside the body to support tissue regeneration and healing. The company is applying the platform across three franchises: bone regeneration, tissue spacing and tissue healing.
Cyclopharm reported its first-half 2026 results in August 2026, describing a fifth consecutive record half. TotalRevenuerose 14% to A$17.5 million, while US Technegas revenue jumped 74% to A$2.1 million from A$1.2 million a year earlier. The company grew its US revenue-generating sites from 35 …
Artrya's core product is Salix, a cloud-based platform that uses artificial intelligence to analyse cardiac CT scans. It comprises three modules: Coronary Anatomy, Coronary Plaque and Coronary Flow. The company advanced its US regulatory pathway, securing FDA clearance for the Salix Coronary Plaque module …
Ramsay reported its FY26 results in late August 2026, and the numbers pointed to a recovering business. The Australian hospital operations showed stronger momentum, supported by higher activity levels, increased case complexity andRevenueindexation flowing from health-fund agreements. In its European arm, Ramsay Santé completed …
CLEO's pivotal development in 2026 was completing a major US clinical-trial milestone. In late March 2026, the company reported that it had enrolled 624 women across 19 specialised US sites and secured 514 blood samples, exceeding its minimum target of 500. That data provides …
Singular Health Group (ASX:SHG) has spent much of 2026 converting a technical achievement into a commercial proposition. In January, the Perth-based medical-imaging software developer secured US Food and Drug Administration 510(k) clearance for 3DICOM MD Cloud, a browser-based platform that turns standard CT, MRI, …